Literature DB >> 27549169

Dendritic Cells Are Dispensable for T Cell Priming and Control of Acute Lymphocytic Choriomeningitis Virus Infection.

Cornelia Hilpert1, Selina Sitte1, Alexander Matthies1, David Voehringer2.   

Abstract

Dendritic cells (DCs) are considered to be the major APCs with potent activity for priming of naive CD4 and CD8 T cells. However, T cell priming can also be achieved by other APCs including macrophages, B cells, or even nonhematopoietic cell types. Systemic low-dose infection of mice with lymphocytic choriomeningitis virus (LCMV) results in massive expansion of virus-specific CD4 and CD8 T cells. To determine the role of DCs as APCs and source of type I IFNs in this infection model, we used ΔDC mice in which DCs are constitutively ablated because of expression of the diphtheria toxin α subunit within developing DCs. ΔDC mice showed lower serum concentrations of IFN-β and IL-12p40, but normal IFN-α levels during the first days postinfection. No differences were found for proliferation of transferred TCR-transgenic cells during the early phase of infection, suggesting that T cell priming occurred with the same efficiency in wild-type and ΔDC mice. Expansion and cytokine expression of endogenous LCMV-specific T cells was comparable between wild-type and ΔDC mice during primary infection and upon rechallenge of memory mice. In both strains of infected mice the viral load was reduced below the limit of detection with the same kinetic. Further, germinal center formation and LCMV-specific Ab responses were not impaired in ΔDC mice. This indicates that DCs are dispensable as APCs for protective immunity against LCMV infection.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27549169     DOI: 10.4049/jimmunol.1502582

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  DNA-binding of the Tet-transactivator curtails antigen-induced lymphocyte activation in mice.

Authors:  Eleonora Ottina; Victor Peperzak; Katia Schoeler; Emma Carrington; Roswitha Sgonc; Marc Pellegrini; Simon Preston; Marco J Herold; Andreas Strasser; Andreas Villunger
Journal:  Nat Commun       Date:  2017-10-18       Impact factor: 14.919

Review 2.  Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.

Authors:  Morgan E Brisse; Hinh Ly
Journal:  Front Immunol       Date:  2019-03-13       Impact factor: 7.561

3.  Linking Cell Dynamics With Gene Coexpression Networks to Characterize Key Events in Chronic Virus Infections.

Authors:  Mireia Pedragosa; Graciela Riera; Valentina Casella; Anna Esteve-Codina; Yael Steuerman; Celina Seth; Gennady Bocharov; Simon Heath; Irit Gat-Viks; Jordi Argilaguet; Andreas Meyerhans
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

4.  IL-33 Augments Virus-Specific Memory T Cell Inflation and Potentiates the Efficacy of an Attenuated Cytomegalovirus-Based Vaccine.

Authors:  James E McLaren; Mathew Clement; Morgan Marsden; Kelly L Miners; Sian Llewellyn-Lacey; Emma J Grant; Anzelika Rubina; Silvia Gimeno Brias; Emma Gostick; Maria A Stacey; Selinda J Orr; Richard J Stanton; Kristin Ladell; David A Price; Ian R Humphreys
Journal:  J Immunol       Date:  2019-02-01       Impact factor: 5.422

5.  The Innate Immune Response to Infection Induces Erythropoietin-Dependent Replenishment of the Dendritic Cell Compartment.

Authors:  Henrik Einwächter; Alexander Heiseke; Andreas Schlitzer; Georg Gasteiger; Heiko Adler; David Voehringer; Markus G Manz; Zsolt Ruzsics; Lars Dölken; Ulrich H Koszinowski; Tim Sparwasser; Wolfgang Reindl; Stefan Jordan
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

6.  Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity.

Authors:  Sarah L Caddy; Marina Vaysburd; Guido Papa; Mark Wing; Kevin O'Connell; Diana Stoycheva; Stian Foss; Jan Terje Andersen; Annette Oxenius; Leo C James
Journal:  EMBO J       Date:  2020-12-01       Impact factor: 14.012

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.